894 related articles for article (PubMed ID: 10160337)
1. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
[TBL] [Abstract][Full Text] [Related]
2. Current good manufacturing practice for blood and blood components; notification of consignees and transfusion recipients receiving blood and blood components at increased risk of transmitting hepatitis C virus infection ("lookback"). Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Aug; 72(164):48765-801. PubMed ID: 17886394
[TBL] [Abstract][Full Text] [Related]
3. Medicare and Medicaid programs; hospital standard for potentially HIV infectious blood and blood products--HCFA. Final rule.
Fed Regist; 1996 Sep; 61(175):47423-34. PubMed ID: 10160338
[TBL] [Abstract][Full Text] [Related]
4. Medicare and Medicaid programs; hospital conditions of participation: laboratory services. Interim final rule with comment period.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2007 Aug; 72(164):48562-74. PubMed ID: 17886393
[TBL] [Abstract][Full Text] [Related]
5. "Guidance for industry: current good manufacturing practice for blood and blood components: (1). Quarantine and disposition of units from prior collections from donors with repeatedly reactive screening test for antibody to hepatitis C virus (anti-HCV); (2). Supplemental testing, and the notification of consignees and blood recipients of donor test results for anti-HCV;" availability--FDA. Notice.
Fed Regist; 1998 Oct; 63(203):56198-9. PubMed ID: 10185838
[TBL] [Abstract][Full Text] [Related]
6. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule.
Fed Regist; 1984 Aug; 49(171):34448-51. PubMed ID: 10299643
[TBL] [Abstract][Full Text] [Related]
7. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
[TBL] [Abstract][Full Text] [Related]
8. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597
[TBL] [Abstract][Full Text] [Related]
9. General requirements for blood, blood components, and blood derivatives; donor notification. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Jun; 66(112):31165-77. PubMed ID: 11725787
[TBL] [Abstract][Full Text] [Related]
10. Medicare and Medicaid programs; hospital conditions of participation: laboratory services. Final rule.
Centers for Medicare & Medicaid Services, HHS
Fed Regist; 2008 Jun; 73(125):36469-71. PubMed ID: 18677830
[TBL] [Abstract][Full Text] [Related]
11. Revisions to the requirements applicable to blood, blood components, and source plasma. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Aug; 66(151):40886-90. PubMed ID: 11732557
[TBL] [Abstract][Full Text] [Related]
12. Requirements for blood and blood components intended for transfusion or for further manufacturing use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2015 May; 80(99):29841-906. PubMed ID: 26003966
[TBL] [Abstract][Full Text] [Related]
13. Revisions to the requirements applicable to blood, blood components and source plasma. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Aug; 72(158):45883-88. PubMed ID: 17847577
[TBL] [Abstract][Full Text] [Related]
14. Exemption of certain transfusion services and clinical laboratories from registration: Food and Drug Administration. Final rule.
Fed Regist; 1980 Dec; 45(251 Pt 1):85727-30. PubMed ID: 10298064
[TBL] [Abstract][Full Text] [Related]
15. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
[TBL] [Abstract][Full Text] [Related]
16. Conditions of participation for hospitals; conditions for coverage of services of independent laboratories; immunohematological testing, transfusion services and bloodbanking: Health Care Financing Administration. Final rule.
Fed Regist; 1981 Aug; 46(157 Pt 1):41059-61. PubMed ID: 10298239
[TBL] [Abstract][Full Text] [Related]
17. Revisions to the requirements applicable to blood, blood components, and source plasma; confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment.
Fed Regist; 2001 Jan; 66(7):1834-7. PubMed ID: 11503754
[TBL] [Abstract][Full Text] [Related]
18. Revisions to labeling requirements for blood and blood components, including source plasma. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2012 Jan; 77(1):7-18. PubMed ID: 22242229
[TBL] [Abstract][Full Text] [Related]
19. Blood and blood components; error and accident reports--Food and Drug Administration. Proposed rule.
Fed Regist; 1980 Aug; 45(155):52821-4. PubMed ID: 10247831
[TBL] [Abstract][Full Text] [Related]
20. Revisions to the requirements applicable to blood, blood components and source plasma; confirmation of effective date and technical amendment. Direct final rule; confirmation of effective date and technical amendment.
Food and Drug Administration, HHS
Fed Regist; 2008 Feb; 73(27):7463-4. PubMed ID: 18389917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
